Automated screening of blood donations for hepatitis C virus RNA using the Qiagen BioRobot 9604 and the Roche COBAS HCV Amplicor assay

Grant, Paul; Sims, C.M.; Krieg-Schneider, F.; Love, Elizabeth M.; Eglin, Roger; Tedder, Richard S.

doi:10.1046/j.1423-0410.2002.00177.x

Cited by 20 publications

(19 citation statements)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 Qualitative PCR was performed using the Amplicor HCV v2.0 MWP assay (Roche Molecular Systems, Pleasanton, CA, USA) with an automated nucleic acid extraction using the BioRobot 9604 (Quiagen, Hilden, Germany). 56 Results are expressed as IU ml -1 (1 IU = approximately 5 RNA copies). Viral genotyping was performed using restriction fragment length polymorphism (RFLP) of the 5' non-coding region.…”

Section: Virologymentioning

confidence: 99%

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation

Wright¹,

Grieve²,

Roberts³

et al. 2006

Health Technol Assess

216

198

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, service-users groups and professional bodies such as Royal Colleges and NHS Trusts.Research suggestions are carefully considered by panels o...

show abstract

Section: Virologymentioning

confidence: 99%

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation

Wright¹,

Grieve²,

Roberts³

et al. 2006

Health Technol Assess

216

198

View full text Add to dashboard Cite

show abstract

“…Due to an increasing demand for molecular tests and for taking advantage of real-time PCR, a fully automated extraction system is considered a prerequisite (18,19,36). Several solutions for nucleic acid (NA) extraction on automated platforms have recently been evaluated for the diagnosis of viral infections (9,11,15,17,20,22,26,27). The COBAS AmpliPrep system (CAP; Roche Diagnostics) is a new instrument designed for rapid high-throughput purification of DNAs and RNAs from biological fluids (such as serum and plasma) (5,14,19,31,33,34).…”

mentioning

confidence: 99%

Evaluation of the COBAS AmpliPrep-Total Nucleic Acid Isolation-COBAS TaqMan Hepatitis B Virus (HBV) Quantitative Test and Comparison to the VERSANT HBV DNA 3.0 Assay

Ronsin¹,

Pillet²,

Bali³

et al. 2006

J Clin Microbiol

View full text Add to dashboard Cite

Quantitative detection of hepatitis B virus (HBV) in serum or plasma has become the most direct and reliable method for monitoring chronic hepatitis B. Here, we report the performance characteristics of a real-time PCR hepatitis B DNA quantitative assay, the COBAS TaqMan (CTM) HBV test (Roche Diagnostics, Meylan, France), in combination with an automated DNA extraction on the COBAS AmpliPrep (CAP) instrument using the total nucleic acid isolation kit (TNAI kit), a generic reagent for nucleic acid isolation (both from Roche Diagnostics). The linearity, accuracy, and specificity of the CAP-TNAI-CTM HBV test were evaluated using various reference panels and standards (HBV panel 2004 from Quality Control for Molecular Diagnostics, OptiQuant HBV panel from AcroMetrix, WHO International Standard for HBV, and Teragenix hepatitis B genotype panel). Quantitative results show that the CAP-TNAI-CTM HBV test performed well with respect to linearity, accuracy, and reproducibility from at least 100 to 500,000 HBV DNA IU/ml. Based on the log 10 IU of HBV DNA/ml measured, the intra-assay variation ranged from 2.49% to 8.46% and the interassay variation ranged from 1.88% to 7.83%. The test was extremely sensitive and could detect samples containing HBV DNA below the reported quantification threshold (<30 IU/ml). All HBV genotypes were correctly amplified, and no cross-contamination occurred during the automated sample preparation. In addition, 402 human serum samples were tested comparatively to the VERSANT HBV DNA 3.0 assay (bDNA; Bayer Diagnostics, Puteaux, France). The viral load results of the CAP-TNAI-CTM test and bDNA were significantly correlated, but the agreement between the two tests was poor, with large differences between results for individual samples. The hands-on time was estimated to be reduced from 2.30 h with bDNA to 45 min with the CAP-TNAI-CTM test, and up to 84 samples were completely processed within a working day. Overall, the performance characteristics of the CAP-TNAI-CTM test demonstrated that it provides a high-throughput sensitive and reliable method for quantitation of HBV DNA levels in the routine molecular laboratory.Hepatitis B virus (HBV) is a major causative agent of chronic hepatitis. Approximately 350 million to 400 million people worldwide are chronically infected. Chronic HBV infection can lead to liver cirrhosis and hepatocellular carcinoma (13). Detection and quantification of HBV DNA in serum or plasma are now considered important indicators for managing disease in HBVinfected patients and predicting and monitoring the efficiency of antiviral treatment as well as identifying the emergence of drug resistance by detecting HBV DNA breakthrough (4, 24). Several commercial molecular tests for the quantitation of HBV DNA in serum or plasma have been developed and are routinely used in diagnostic virology laboratories (10, 29). These molecular tests are based on target amplification (HBV Monitor test; Roche Diagnostics, Meylan, France), branched-DNA signal amplification (VERSANT HBV DNA 3.0 assa...

show abstract

“…Automation of viral nucleic acid detection using silica magnetic bead technology has been reported for enteroviruses, hepatitis B, hepatitis C, Epstein-Barr virus, herpes simplex virus, human papillomavirus, influenza B and SARS virus (Cheng et al, 2004;Cuschieri et al, 2003;Espy et al, 2001;Fafi-Kremer et al, 2004;Grant et al, 2002;Knepp et al, 2003;Petrich et al, 2006;Shi et al, 2001). This study applies automation using magnetic beads to influenza A detection.…”

Section: Discussionmentioning

confidence: 99%

Automated extraction of avian influenza virus for rapid detection using real-time RT-PCR

Tewari

Zellers

Acland

et al. 2007

Journal of Clinical Virology

View full text Add to dashboard Cite

Automated screening of blood donations for hepatitis C virus RNA using the Qiagen BioRobot 9604 and the Roche COBAS HCV Amplicor assay

Cited by 20 publications

References 22 publications

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation

Evaluation of the COBAS AmpliPrep-Total Nucleic Acid Isolation-COBAS TaqMan Hepatitis B Virus (HBV) Quantitative Test and Comparison to the VERSANT HBV DNA 3.0 Assay

Automated extraction of avian influenza virus for rapid detection using real-time RT-PCR

Contact Info

Product

Resources

About